Search

Displaying results 3231 - 3240 of 10000 in total
  1. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    [A275508] Specifically, vepdegestrant is being developed as a first-line or subsequent treatment option for patients whose tumors grow in response to estrogen and have progressed after standard therapies … [A275507, A275509] In a global, randomized Phase III clinical trial (VERITAC-2), vepdegestrant was clinically evaluated and compared against the injectable selective estrogen receptor degrader (SERD) [

  2. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. It is also used to boost the immune response in the treatment of other diseases. … Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide.

  3. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  4. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.

  5. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065] … endochondral ossification, resulting in multisystem complications including short stature.

  6. Drug

    Embusartan

    go.drugbank.com/drugs/DB19949
    Experimental

    Embusartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Embusartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

    Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor Blockers
  7. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    [A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … [A198771,A198777,A193800] Camostat mesylate was first approved in Japan in January 2006.[L13197]

  8. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.

    Synonyms: N,2-Dimethyl-2-phenylsuccinimide, alpha-Methyl-alpha-phenyl N-methyl succinimide
  9. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema). … Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

  10. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]